Protocol Ledger

NCT04269902 · Phase III · RECRUITING

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Interventional Phase III clinical trial protocol NCT04269902 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-02 Enrollment: 247 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04269902
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)247 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04269902
Protocol FieldVerified Registry Value
NCT IdentifierNCT04269902
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment247 participants (ESTIMATED)
Registered Start Date2021-03-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI